Cell Therapy / CAR-T / CRISPR
Biotech Modality · Active
· Health Care
Latest report
2026-05-01 13:51
Biotech companies developing cell-based therapies including CAR-T immunotherapy, CRISPR genome editing, autologous cell platforms.
Pool
86
Industries
6
Cohort
26
Cohort MCap
34.1B
Layers
4
Topology Rationale
The cell therapy value chain starts with developers creating autologous, allogeneic, CAR-T, CRISPR, and regenerative medicine products, then relies on specialized tools, bioprocessing, cold-chain, and clinical-development infrastructure to manufacture and validate these complex therapies. Demand and commercialization are shaped by large biopharma partners and by the hospitals, labs, and care sites that diagnose eligible patients and administer treatment, while general medtech and unrelated biopharma names are excluded when they do not directly map to this workflow.
Value-Chain Layers
1
Cell Therapy, Gene Editing & Regenerative Medicine Developers
Companies in this layer develop and commercialize cell-based, gene-edited, and related advanced therapies that sit at the center of the theme.
11 companies
| Company | Role | Market Cap | Revenue ($M) | Cash & Equivalents ($M) | Total Assets ($M) | EPS Diluted (GAAP) |
|---|---|---|---|---|---|---|
|
Crispr Therapeutics AG
CRSP
FY2025
|
CRISPR gene-editing platform and ex vivo therapy developer
Healthcare
|
4.9B | 4 | 348 | 2,265 | -6.47 |
|
Legend Biotech Corp
|
CAR-T developer with commercial cell therapy exposure
Healthcare
|
4.2B | — | — | — | — |
|
Vericel Corp Ord
VCEL
FY2025
|
Commercial regenerative cell therapy products
Healthcare
|
1.7B | 276 | — | — | — |
|
Intellia Therapeutics Inc
NTLA
FY2025
|
Gene-editing therapeutics focused on CRISPR-based medicines
Healthcare
|
1.5B | — | 605 | 842 | -3.81 |
|
Amgen Inc
AMGN
Q1-2026
|
Biotech with cell therapy exposure through T-cell engager and oncology pipeline
Healthcare
|
182.2B | 8,618 | 12,038 | 92,504 | 3.34 |
|
Gilead Sciences Inc
GILD
FY2025
|
Owns commercial CAR-T franchise within oncology
Healthcare
|
159.9B | 29,443 | 10,605 | 59,023 | 6.78 |
|
Vertex Pharmaceuticals Inc
VRTX
FY2025
|
Commercial gene-edited therapy exposure via Casgevy
Healthcare
|
107.7B | 12,001 | 12,320 | 25,643 | 15.32 |
|
Regeneron Pharmaceuticals Inc
REGN
Q1-2026
|
Biotech with meaningful cell and gene therapy R&D activity
Healthcare
|
72.0B | — | — | — | — |
|
BioNTech SE
|
Oncology and cell therapy platform developer
Healthcare
|
25.7B | — | — | — | — |
|
United Therapeutics Corporation
UTHR
FY2025
|
Regenerative medicine and organ/cell therapy adjacent biotech
Healthcare
|
25.0B | 3,183 | — | 7,880 | 27.86 |
|
Moderna Inc
MRNA
Q1-2026
|
Advanced therapeutics platform with cell therapy and engineered-cell programs
Healthcare
|
18.1B | 389 | 1,908 | 11,488 | -3.4 |
2
Bioprocessing, Cryopreservation, Testing & Cell-Therapy Development Services
This layer supplies the research services, analytical tools, manufacturing support, sterilization, and cold-chain capabilities required to develop, store, and produce cell therapies.
13 companies
| Company | Role | Market Cap | Revenue ($M) | Gross Margin (%) | Operating Cash Flow ($M) | Capex ($M) | Free Cash Flow ($M) |
|---|---|---|---|---|---|---|---|
|
Thermo Fisher Scientific Inc
TMO
Q1-2026
|
Life sciences solutions and biopharma services supplier
Healthcare
|
173.3B | 11,005 | 40.7% | 1,192 | 376 | 825 |
|
Danaher Corporation
DHR
Q1-2026
|
Broad bioprocess and life sciences tools exposure
Healthcare
|
126.5B | 5,951 | 60.4% | 1,322 | 237 | 1,085 |
|
Abbott Laboratories
ABT
Q1-2026
|
Diagnostics and lab tools support therapy development workflows
Healthcare
|
158.7B | 11,164 | 52.4% | — | — | — |
|
Agilent Technologies Inc
A
Q1-2026
|
Analytical and life sciences instrumentation provider
Healthcare
|
31.5B | 1,798 | — | 268 | 93 | 175 |
|
Waters Corporation
WAT
FY2025
|
Analytical chemistry tools used in bioprocess QA/QC
Healthcare
|
28.7B | 3,165 | — | 653 | 113 | — |
|
Becton Dickinson and Company
BDX
Q1-2026
|
Biopharma systems and life sciences consumables supplier
Healthcare
|
41.3B | 5,252 | 45.9% | 657 | 108 | 549 |
|
IQVIA Holdings Inc
IQV
FY2025
|
R&D solutions and clinical development services
Healthcare
|
26.3B | 16,310 | — | 2,654 | 603 | 2,051 |
|
Laboratory Corporation of America Holdings
LH
Q1-2026
|
Biopharma laboratory services and diagnostics support
Healthcare
|
21.2B | 3,538 | 28.7% | 192 | 121 | 70 |
|
STERIS plc
STE
Q3-FY2026
|
Sterilization and life sciences services for advanced therapies
Healthcare
|
20.9B | 1,496 | — | 1,006 | 279 | 738 |
|
Illumina Inc
ILMN
FY2025
|
Sequencing platform used in gene editing and cell characterization
Healthcare
|
18.3B | 4,343 | — | 1,079 | 148 | 931 |
|
Medpace Holdings Inc
MEDP
Q1-2026
|
CRO supporting clinical development programs
Healthcare
|
11.8B | 707 | — | 152 | 7 | — |
|
Lineage, Inc. Common Stock
LINE
FY2025
|
Cold-chain warehousing and logistics relevant to cell therapy handling
Real Estate
|
8.9B | 5,355 | — | 943 | 747 | 196 |
|
Charles River Laboratories
CRL
Q4-2025
|
Preclinical and research services for advanced therapeutics
Healthcare
|
8.1B | — | — | — | — | — |
3
Strategic Biopharma Partners, Commercialization Platforms & Capital Providers
Large pharmaceutical and related platform companies in this layer shape funding, partnerships, licensing, commercialization, and benchmark economics for cell and gene therapies.
14 companies
| Company | Role | Market Cap | Revenue ($M) | Gross Margin (GAAP) (%) | Net Income (GAAP) ($M) | EPS Diluted (GAAP) |
|---|---|---|---|---|---|---|
|
Eli Lilly and Company
LLY
Q1-2026
|
Large pharma partner and acquirer of external innovation
Healthcare
|
760.4B | 19,799 | 81.9% | 7,396 | 8.26 |
|
Johnson & Johnson
JNJ
Q1-2026
|
Global pharma with oncology commercialization capabilities
Healthcare
|
547.3B | 24,062 | — | 5,235 | 2.14 |
|
AbbVie Inc
ABBV
Q1-2026
|
Large biopharma capital source for partnered assets
Healthcare
|
360.6B | 15,002 | 71.9% | — | 0.39 |
|
AstraZeneca PLC
|
Global pharma partner for advanced therapeutics programs
Healthcare
|
287.1B | — | — | — | — |
|
Merck & Company Inc
MRK
Q1-2026
|
Large oncology-focused pharma partner and acquirer
Healthcare
|
274.0B | 16,286 | 74.2% | -4,240 | -1.72 |
|
Novartis AG ADR
|
Commercial cell therapy player and global launch infrastructure
Healthcare
|
272.7B | — | — | — | — |
|
Novo Nordisk A/S
|
Large pharma capital allocator adjacent to advanced therapies
Healthcare
|
178.7B | — | — | — | — |
|
Pfizer Inc
PFE
FY2025
|
Pharma company with business development and oncology reach
Healthcare
|
149.4B | 62,579 | 74.3% | 7,771 | 1.36 |
|
Bristol-Myers Squibb Company
BMY
Q1-2026
|
Owns Breyanzi and cell therapy commercialization capabilities
Healthcare
|
123.7B | 11,489 | 70.2% | 2,677 | 1.31 |
|
Sanofi ADR
|
Large pharma partner for rare disease and advanced therapies
Healthcare
|
110.3B | — | — | — | — |
|
Takeda Pharmaceutical Co Ltd ADR
|
Global pharma with cell therapy and plasma/oncology adjacency
Healthcare
|
51.5B | — | — | — | — |
|
Royalty Pharma Plc
RPRX
FY2025
|
Provides capital via royalty financing across biotech assets
Healthcare
|
29.3B | — | — | 1,324 | — |
|
Jazz Pharmaceuticals PLC
JAZZ
FY2025
|
Oncology-focused pharma with partnering relevance
Healthcare
|
12.5B | 4,268 | 87.5% | -356 | -5.84 |
|
Dr. Reddy’s Laboratories Ltd ADR
|
Pharma manufacturing and partnership platform adjacent to commercialization
Healthcare
|
11.5B | — | — | — | — |
4
Diagnostics, Patient Identification & Treatment Delivery Sites
These companies enable patient finding, testing, referral, and administration of complex therapies through diagnostic services, oncology workflows, and provider care settings.
8 companies
| Company | Role | Market Cap | Revenue ($M) | Operating Cash Flow ($M) | Capex ($M) | Net Income (GAAP) ($M) |
|---|---|---|---|---|---|---|
|
HCA Holdings Inc
HCA
Q1-2026
|
Hospital network and site of care for therapy administration
Healthcare
|
96.7B | 19,109 | 2,014 | 1,119 | 1,857 |
|
Natera Inc
NTRA
FY2025
|
Genetic testing and patient identification infrastructure
Healthcare
|
27.8B | 2,300 | — | — | — |
|
Quest Diagnostics Incorporated
DGX
Q1-2026
|
Diagnostic lab network supporting testing workflows
Healthcare
|
21.0B | 2,895 | 278 | 114 | 252 |
|
EXACT Sciences Corporation
EXAS
FY2025
|
Precision oncology testing helps identify eligible patients
Healthcare
|
20.0B | 3,247 | 491 | 135 | -208 |
|
Tenet Healthcare Corporation
THC
FY2025
|
Hospital operator and downstream treatment site
Healthcare
|
15.5B | — | — | — | — |
|
Fresenius Medical Care Corporation
|
Clinical care delivery network within healthcare services
Healthcare
|
12.1B | — | — | — | — |
|
Guardant Health Inc
GH
FY2025
|
Precision oncology liquid biopsy and monitoring tools
Healthcare
|
11.1B | 981 | -185 | 48 | — |
|
The Ensign Group Inc
ENSG
FY2025
|
Healthcare facilities operator within downstream care infrastructure
Healthcare
|
10.9B | 5,058 | 564 | 513 | 344 |
Report History
| Generated | Pool | Layers |
|---|---|---|
| 2026-05-01 13:51 | 86 | 4 |